IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio’s CEO will speak and meet investors at the H.C. Wainwright Global Investment Conference, with online webcast access available.

Rhea-AI Summary

IN8bio (INAB) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, in New York.

Chief Executive Officer and Co-Founder William Ho will present at 10:00 a.m. ET in the Kennedy II room on the 4th floor of the Lotte New York Palace Hotel. Ho and other members of the management team will also hold one-on-one meetings with investors throughout the conference. A live webcast of the presentation, along with a replay after the event, will be accessible via the Investors section of IN8bio’s website.

Key Terms

gamma-delta, t cell engagers

2 terms

gamma-delta medical

"developing innovative gamma-delta (γδ) T cell therapies"

A subset of immune cells known as gamma-delta T cells, defined by the specific protein chains—gamma and delta—on their surface that distinguish them from the more common alpha-beta T cells. They can recognize and respond to stressed, infected, or cancerous cells in ways different from other immune cells, so they matter to investors because they are a target or platform for drug and cell-therapy development and can be used as biomarkers in clinical programs.

t cell engagers medical

"and T cell engagers for cancer and autoimmune diseases"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026
Time: 10:00 a.m. ET
Format: Fireside Chat
Presenter: William Ho, Chief Executive Officer and Co-Founder
Location: Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City
Webcast: Webcast Link

A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

When and where is IN8bio’s fireside chat at the H.C. Wainwright conference?

The fireside chat is scheduled for Monday, September 14, 2026, at 10:00 a.m. ET. It will take place in the Kennedy II room on the 4th floor of the Lotte New York Palace Hotel in New York City.

How can investors access IN8bio’s presentation if they are not attending in person?

A live webcast of the fireside chat will be available through the Investors section of IN8bio’s website via the provided webcast link. A replay will also be available after the event.

Will IN8bio management be available for individual investor meetings during the conference?

Yes. William Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the H.C. Wainwright 28th Annual Global Investment Conference.